Skip to main content
. Author manuscript; available in PMC: 2020 Sep 15.
Published in final edited form as: Clin Cancer Res. 2019 Dec 18;26(6):1309–1317. doi: 10.1158/1078-0432.CCR-19-2829

Figure 3: 5-hmC profiling matches clinical response by INRC.

Figure 3:

Each patient with two or more samples in the Discovery and Validation cohorts are shown. 5-hmC Cluster assignments are highlighted in the box and the INRC response classification at that time point is written. All cfDNA was collected at the beginning of the timepoint. Clinical response was determined using the 2017 INRC comparing each timepoint to diagnosis or prior assessment for relapsed patients. Abbreviations: Tx; Therapy, Dx; Diagnosis, Ind; Induction, Brid; Bridge therapy per ANBL1221, Con; first consolidative transplant, Con2; second consolidative transplant Imm; Immunotherapy, Fu; follow up, SD; Stable Disease, MR; Minor Response, PR; Partial Response, CR: Complete Response, PD; Progressive Disease, HR; high-risk, IR; intermediate-risk, NA; Not applicable.